Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

BACKGROUND: Secukinumab [an interleukin (IL)‐17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL‐12/23 inhibitor) in patients with moderate‐to‐severe plaque psoriasis. OBJECTIVES: To report 52‐week results from a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, A.B., Merola, J.F., Reich, K., Behrens, F., Nash, P., Griffiths, C.E.M., Bao, W., Pellet, P., Pricop, L., McInnes, I.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291158/
https://www.ncbi.nlm.nih.gov/pubmed/33913511
http://dx.doi.org/10.1111/bjd.20413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291158/
https://www.ncbi.nlm.nih.gov/pubmed/33913511
http://dx.doi.org/10.1111/bjd.20413

Ejemplares similares